Authors: MALERCZYK C FUCHS B BELZ GG ROLL S BUTZER R BREITHAUPTGROGLER K HERRMANN V MAGIN SG HOGEMANN A VOITH B MUTSCHLER E

Citation: C. Malerczyk et al., ANGIOTENSIN-II ANTAGONISM AND PLASMA RADIORECEPTOR-KINETICS OF CANDESARTAN IN MAN, British journal of clinical pharmacology, 45(6), 1998, pp. 567-573

Authors: HOOGKAMER JFW KLEINBLOESEM CH OUWERKERK M HOGEMANN A NOKHODIAN A KIRCH W WEIDEKAMM E

Citation: Jfw. Hoogkamer et al., PHARMACOKINETICS AND SAFETY OF CANDESARTAN CILEXETIL IN SUBJECTS WITHNORMAL AND IMPAIRED LIVER-FUNCTION, European Journal of Clinical Pharmacology, 54(4), 1998, pp. 341-345

Authors: JONKMAN JHG VANLIER JJ VANHEININGEN PNM LINS R SENNEWALD R HOGEMANN A

Citation: Jhg. Jonkman et al., PHARMACOKINETIC DRUG-INTERACTION STUDIES WITH CANDESARTAN CILEXETIL, Journal of human hypertension, 11, 1997, pp. 31-35

Authors: MEINEKE I FELTKAMP H HOGEMANN A GUNDERTREMY U

Citation: I. Meineke et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF CANDESARTAN AFTER ADMINISTRATION OF ITS PRO-DRUG CANDESARTAN CILEXETIL IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION - A POPULATION ANALYSIS, European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 221-228

Authors: DINGEMANSE J KLEINBLOESEM CH HOOGKAMER JFW OUWERKERK M HOGEMANN A NOKHODIAN A

Citation: J. Dingemanse et al., COMPARATIVE PHARMACOKINETICS OF MULTIPLE-DOSE CANDESARTAN IN SUBJECTSWITH AND WITHOUT IMPAIRED HEPATIC-FUNCTION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 61-61